Table 1 Mycobacterium tuberculosis samples (N = 535).
From: Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan
Characteristic | Group | N | % |
|---|---|---|---|
Lineage | 1 | 22 | 4.1 |
2 | 36 | 6.7 | |
3 | 397 | 74.2 | |
4 | 80 | 15.0 | |
Drug resistance statusa | Sensitive | 60 | 11.2 |
Pre-MDR | 31 | 5.8 | |
MDR | 328 | 61.3 | |
Pre-XDR | 47 | 8.8 | |
XDR | 66 | 12.3 | |
Other | 3 | 0.6 | |
Individual drug resistancea | Rifampicin | 460 | 86.0 |
Isoniazid | 435 | 81.3 | |
Ethambutol | 385 | 72.0 | |
Pyrazinamide | 258 | 48.2 | |
Streptomycin | 238 | 44.5 | |
Ofloxacin | 277 | 51.8 | |
Moxifloxacin | 277 | 51.8 | |
Levofloxacin | 277 | 51.8 | |
Amikacin | 75 | 14.0 | |
Kanamycin | 79 | 14.8 | |
Capreomycin | 78 | 14.6 | |
Ciprofloxacin | 277 | 51.8 | |
Ethionamide | 102 | 19.1 | |
Para aminosalicylic acid | 10 | 1.9 | |
Cycloserine | 2 | 0.4 | |
Clofazimine | 1 | 0.2 | |
Bedaquiline | 1 | 0.2 | |
Fluoroquinolones | 277 | 51.8 | |
Aminoglycosides | 75 | 14.0 | |
Collection year | 2003—2005 | 49 | 9.2 |
2015—2017 | 438 | 81.9 | |
2018—2020 | 48 | 9.0 | |
Region | Peshawar | 77 | 14.4 |
Dera Ismail Khan | 25 | 4.7 | |
Abbottabad | 13 | 2.4 | |
Swat | 13 | 2.4 | |
Rawalpindi | 7 | 1.3 | |
Hyderabad | 5 | 0.9 | |
Karachi | 5 | 0.9 | |
Lahore | 5 | 0.9 | |
Other | 13 | 2.4 | |
Missing | 372 | 69.5 |
